Oral Outpatient Antibiotic Regimens for Community-Acquired Pneumonia
For otherwise healthy adults without comorbidities, amoxicillin 1 g three times daily for 5–7 days is the preferred first-line oral therapy, with doxycycline 100 mg twice daily as an acceptable alternative; patients with comorbidities require combination therapy with a β-lactam plus macrolide or respiratory fluoroquinolone monotherapy. 1, 2
Previously Healthy Adults (No Comorbidities)
First-Line Therapy
Amoxicillin 1 g orally three times daily for 5–7 days is the preferred first-line agent because it retains activity against 90–95% of Streptococcus pneumoniae isolates, including many penicillin-resistant strains, and provides superior pneumococcal coverage compared with oral cephalosporins. 1, 2
Doxycycline 100 mg orally twice daily for 5–7 days serves as an acceptable alternative, offering coverage of both typical bacterial pathogens (S. pneumoniae, H. influenzae, M. catarrhalis) and atypical organisms (Mycoplasma pneumoniae, Chlamydophila pneumoniae, Legionella pneumophila). 1, 2
Macrolide Use (Restricted)
Macrolides (azithromycin 500 mg day 1, then 250 mg daily days 2–5; or clarithromycin 500 mg twice daily) should only be used when local pneumococcal macrolide resistance is documented to be <25%. 1, 2
In most U.S. regions, macrolide resistance among S. pneumoniae is 20–30%, making macrolide monotherapy unsafe as first-line therapy. 1, 2
Macrolide monotherapy should never be used in areas where pneumococcal macrolide resistance exceeds 25%, as breakthrough pneumococcal bacteremia occurs significantly more frequently with resistant strains. 1, 2
Adults with Comorbidities or Recent Antibiotic Use
Combination Therapy (Preferred)
Amoxicillin-clavulanate 875 mg/125 mg orally twice daily PLUS azithromycin 500 mg day 1, then 250 mg daily days 2–5 is the preferred combination regimen for patients with chronic heart, lung, liver, or renal disease; diabetes; alcoholism; malignancy; asplenia; immunosuppression; or recent antibiotic use within 90 days. 1, 2
This combination achieves approximately 91.5% favorable clinical outcomes by covering typical bacteria and atypical pathogens. 1, 2
Alternative β-lactams (cefpodoxime 200 mg twice daily or cefuroxime 500 mg twice daily) can be substituted for amoxicillin-clavulanate, but must always be combined with a macrolide or doxycycline. 1, 2
Doxycycline 100 mg twice daily can substitute for the macrolide component if azithromycin is unavailable or contraindicated. 1
Respiratory Fluoroquinolone Monotherapy (Alternative)
Levofloxacin 750 mg orally once daily for 5–7 days or moxifloxacin 400 mg orally once daily for 5–7 days may be used when β-lactams or macrolides are contraindicated. 1, 2, 3
Fluoroquinolones are active against >98% of S. pneumoniae isolates, including penicillin-resistant strains. 1, 2
Fluoroquinolones should be reserved for patients with comorbidities or when combination therapy is contraindicated due to FDA warnings about serious adverse events (tendon rupture, peripheral neuropathy, aortic dissection) and rising resistance. 1, 2
Patients with Severe β-Lactam Allergy
Anaphylactic or Severe Allergy
Respiratory fluoroquinolone monotherapy (levofloxacin 750 mg daily or moxifloxacin 400 mg daily) is the preferred alternative for patients with documented severe β-lactam allergy. 1, 2
Doxycycline 100 mg twice daily is an acceptable alternative for healthy adults without comorbidities who have a β-lactam allergy. 1, 2
Avoid cephalosporins in patients with documented anaphylactic penicillin allergy due to 1–10% cross-reactivity risk. 1
Treatment Duration and Monitoring
Standard Duration
Minimum treatment duration is 5 days, continuing until the patient is afebrile for 48–72 hours with no more than one sign of clinical instability. 1, 2
Typical total duration for uncomplicated CAP is 5–7 days. 1, 2
Extended courses (14–21 days) are required only for infections caused by Legionella pneumophila, Staphylococcus aureus, or Gram-negative enteric bacilli. 1, 2
Clinical Stability Criteria
- Temperature ≤37.8°C, heart rate ≤100 bpm, respiratory rate ≤24 breaths/min, systolic blood pressure ≥90 mmHg, oxygen saturation ≥90% on room air, ability to maintain oral intake, and normal mental status. 1
Follow-Up
Clinical review at 48 hours (or sooner if symptoms worsen) to assess response, oral intake, and adherence. 1, 2
Routine follow-up at 6 weeks for all patients; chest radiograph only if symptoms persist, physical signs remain, or high risk for underlying malignancy (e.g., smokers >50 years). 1, 2
Treatment Failure Recognition and Escalation
Indicators of Treatment Failure
No clinical improvement by day 2–3 warrants reassessment and potential antibiotic change. 1, 2
Development of respiratory distress (respiratory rate >30/min, oxygen saturation <92%), hemodynamic instability (systolic blood pressure <90 mmHg), inability to tolerate oral antibiotics, or new complications such as pleural effusion. 1, 2
Escalation Strategy
If amoxicillin monotherapy fails, add or substitute a macrolide (azithromycin or clarithromycin) to cover atypical pathogens. 1, 2
If combination therapy (β-lactam + macrolide/doxycycline) fails, switch to a respiratory fluoroquinolone (levofloxacin 750 mg daily or moxifloxacin 400 mg daily). 1, 2
Hospital referral is mandatory if the patient develops respiratory distress, hypoxemia, or hemodynamic instability. 1, 2
Critical Pitfalls to Avoid
Never use macrolide monotherapy in areas where pneumococcal macrolide resistance exceeds 25% (most of the United States), as this leads to treatment failure and breakthrough bacteremia. 1, 2
Avoid indiscriminate fluoroquinolone use in uncomplicated outpatient CAP due to FDA warnings about serious adverse events and resistance concerns; reserve for patients with comorbidities or treatment failure. 1, 2
Oral cephalosporins (cefuroxime, cefpodoxime) are not first-line agents due to inferior in-vitro activity against S. pneumoniae, lack of atypical coverage, higher cost, and no demonstrated clinical superiority. 1, 2
Do not use amoxicillin-clavulanate monotherapy; always combine with a macrolide to ensure atypical pathogen coverage. 1, 2
If the patient used antibiotics within the past 90 days, select an agent from a different antibiotic class to reduce resistance risk. 1, 2
Special Populations
COPD or Asthma Patients
Patients with COPD or asthma require combination therapy even in the outpatient setting due to increased risk of Pseudomonas aeruginosa and other resistant pathogens. 1, 2
Respiratory fluoroquinolones are specifically recommended for COPD patients who have received systemic antibiotics or oral corticosteroids within the preceding three months. 1
Suspected Aspiration Pneumonia
Amoxicillin-clavulanate 875 mg/125 mg twice daily PLUS azithromycin is the preferred regimen to ensure anaerobic coverage. 1, 2
Clindamycin is an alternative for patients with β-lactam allergy. 1
Prevention and Vaccination
Pneumococcal polysaccharide vaccine should be offered to all adults ≥65 years and those with high-risk conditions. 1, 2
Annual influenza vaccination is recommended for all patients, especially those with chronic medical illnesses. 1, 2
Smoking cessation counseling should be provided to all current smokers. 1, 2